Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q3

4483.TEDINET S100SUYD
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥22.3bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥8.5bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥27.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥19.5bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥7.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥5.7bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥2.1bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥4.0bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥1.8bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥5.6bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥2.0bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥5.9bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥4.0bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥1.8bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥4.0bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.3bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.7bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥4.0bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥1.3bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥2.7bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥1.2bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥103.6bnat 2023-12-31Cons.Assets IFRS
Total assets¥98.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥95.1bnat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥33.6bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥34.0bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥70.0bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥64.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥62.9bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥70.0bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥64.5bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥62.9bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥17.0bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥22.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥21.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥1.2bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥4.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥2.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥9.4bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥21.8bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥2.4bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥28.3bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥27.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥62.312023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥20.142023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥71.172022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥44.982022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.282022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥60.442023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.912023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥67.692022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥42.662022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥18.452022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio67.5%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio65.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.1%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 71
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥102m
Reconciling Itemsreconcilingrevenue2023-10-01 → 2023-12-31−¥12m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥102m
Reconciling Itemsreconcilingrevenue intersegment2023-10-01 → 2023-12-31−¥12m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥515m
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2023-12-31−¥176m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-04-01 → 2023-12-31¥1.6bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-10-01 → 2023-12-31¥301m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-04-01 → 2023-12-31¥1.5bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-10-01 → 2023-12-31¥301m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥50m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-04-01 → 2023-12-31¥175m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-10-01 → 2023-12-31¥41m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2023-04-01 → 2023-12-31¥16.6bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2023-10-01 → 2023-12-31¥6.8bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-04-01 → 2023-12-31¥16.6bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-10-01 → 2023-12-31¥6.8bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥51m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥12m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-04-01 → 2023-12-31¥5.0bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-10-01 → 2023-12-31¥2.5bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2023-04-01 → 2023-12-31¥4.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2023-10-01 → 2023-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2023-04-01 → 2023-12-31¥4.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2023-10-01 → 2023-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2023-04-01 → 2023-12-31¥1.6bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2023-10-01 → 2023-12-31¥556m
—segment totalrevenue2023-04-01 → 2023-12-31¥22.4bn
—segment totalrevenue2023-10-01 → 2023-12-31¥8.5bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥22.3bn
—segment totalrevenue external2023-10-01 → 2023-12-31¥8.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥102m
—segment totalrevenue intersegment2023-10-01 → 2023-12-31¥12m
—segment totalsegment profit2023-04-01 → 2023-12-31¥6.7bn
—segment totalsegment profit2023-10-01 → 2023-12-31¥3.1bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥189m
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥62m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥189m
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥62m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥417m
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥227m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-12-31¥2.8bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-10-01 → 2022-12-31¥944m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-12-31¥2.7bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-10-01 → 2022-12-31¥901m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥127m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥43m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-12-31¥310m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-10-01 → 2022-12-31¥118m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2022-10-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-10-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥62m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥19m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-12-31¥4.0bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-10-01 → 2022-12-31¥2.0bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2022-10-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2022-10-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2022-10-01 → 2022-12-31¥492m
—segment totalrevenue2022-04-01 → 2022-12-31¥19.7bn
—segment totalrevenue2022-10-01 → 2022-12-31¥7.5bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥19.5bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥7.5bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥189m
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥62m
—segment totalsegment profit2022-04-01 → 2022-12-31¥5.7bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 846
ItemContextValueUnit
Repayments of short term borrowings fin cf IFRSCurrentYTDDuration-264000000JPY
Proceeds from long term borrowings fin cf IFRSPrior1YTDDuration961000000JPY
Proceeds from long term borrowings fin cf IFRSCurrentYTDDuration2528000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-1187000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-2327000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-656000000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-690000000JPY
Proceeds from issuance of shares fin cf IFRSPrior1YTDDuration29212000000JPY
Proceeds from issuance of shares fin cf IFRSCurrentYTDDuration－JPY
Proceeds from exercise of share acquisition rights fin cf IFRSPrior1YTDDuration309000000JPY
Proceeds from exercise of share acquisition rights fin cf IFRSCurrentYTDDuration2197000000JPY
Dividends paid fin cf IFRSPrior1YTDDuration-564000000JPY
Dividends paid fin cf IFRSCurrentYTDDuration-754000000JPY
Other fin cf IFRSPrior1YTDDuration12000000JPY
Other fin cf IFRSCurrentYTDDuration5000000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration27874000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration2395000000JPY
Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRSPrior1YTDDuration8562000000JPY
Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRSCurrentYTDDuration-5799000000JPY
Cash and cash equivalents IFRSPrior2YearInstant13192000000JPY
Cash and cash equivalents IFRSPrior1YearInstant22782000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration-0JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration0JPY
Cash and cash equivalents IFRSPrior1QuarterInstant21754000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant16983000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000HealthcareBigDataReportableSegmentMember13081000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000TeleMedicineReportableSegmentMember3799000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000DispensingPharmacySupportReportableSegmentMember2661000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember19542000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration19542000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000HealthcareBigDataReportableSegmentMember62000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000TeleMedicineReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000DispensingPharmacySupportReportableSegmentMember127000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember189000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-189000000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000HealthcareBigDataReportableSegmentMember13144000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000TeleMedicineReportableSegmentMember3799000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000DispensingPharmacySupportReportableSegmentMember2788000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember19732000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-189000000JPY
Revenue IFRSPrior1YTDDuration19542000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000HealthcareBigDataReportableSegmentMember4022000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000TeleMedicineReportableSegmentMember1416000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E35308-000DispensingPharmacySupportReportableSegmentMember310000000JPY
Segment profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember5749000000JPY
Segment profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-417000000JPY
Segment profit loss IFRSPrior1YTDDuration5332000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E35308-000HealthcareBigDataReportableSegmentMember16597000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass